We are live on
!
Find out more
TG
TLP Group Portfolio holdings
AUM
$6.61M
1-Year Est. Return
12.46%
This Fund
S&P 500
This Quarter
Est. Return
+1.14%
1 Year Est. Return
-12.46%
3 Year Est. Return
+42.65%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.39M
AUM Growth
-$1.79M
(-25%)
Cap. Flow
+$42.5M
Cap. Flow
% of AUM
788.4%
Top 10 Holdings %
Top 10 Hldgs %
95.81%
Holding
17
New
4
Increased
6
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$21.2M |
| 2 |
Pfizer
PFE
|
+$9.48M |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$8.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$2.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 5.92% |
Similar funds
LAM
SPCP
GZ
RGNCM
FCM
DCM
DAL
SAM
TLP Group's Q2 2019 Portfolio in Review
As of Q2 2019, TLP Group held 17 positions worth $5.39M, down 25% from $7.18M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
TLP Group deployed $42.5M of net new capital in Q2 2019, opening 4 new positions and adding to 6 existing holdings. Its largest new stake was Merck: 276,462 shares worth $221K.
By sector, the portfolio is most concentrated in Healthcare at 5.9% of assets.
On the sell side, the most notable exit was iShares Biotechnology ETF, an estimated $2.5M sold.
- TLP Group's largest Q2 2019 buy was Merck: 276,462 shares worth $221K.
- TLP Group fully exited iShares Biotechnology ETF in Q2 2019, selling an estimated $2.5M.
- TLP Group's ten largest holdings make up 96% of its $5.39M portfolio in Q2 2019.
- TLP Group opened 4 new positions and closed 3 in Q2 2019.
- TLP Group's portfolio value fell 25% quarter-over-quarter to $5.39M.
Based on TLP Group's 13F filing for Q2 2019, filed 16 Jul 2019.